Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck
David J. Sher(DePaul University), Roy B. Tishler(Dana-Farber Cancer Institute), Lori J. Wirth(Massachusetts General Hospital), Laura A. Goguen(Brigham and Women's Hospital), Donald J. Annino(Harvard University), Charles M. Norris, Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Tracy A. Balboni(Brigham and Women's Hospital)
International Journal of Radiation Oncology*Biology*Physics
December 21, 2010
Cited by 55
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926